KLRG1 and glioblastoma: Comparable to glioblastoma patients, RRMS patients had higher fractions of KLRG1+CD4+ TTE (Tc-I 25) and reduced percentages of KLRG1+CD4+ TTM (Tc-I 6), KLRG1+CD4+ TCM (Tc-I 3), CD4+ TEM (Tc-I 11), and Th9 (Tc-II 7) compared to controls (Fig. 5H-J, L, N).